Clinical examples

In clinical trials, XHANCE significantly improved nasal congestion at Week 4 and significantly reduced bilateral polyp grade at Week 16 (coprimary endpoints)1:

  • Average reduction in congestion using a 0-3 point scale: 0.62 XHANCE 372 mcg BID vs 0.24 placebo EDS (P<0.001)
  • Average reduction of polyp grade in a clinical trial using a 0-3 point scale: 1.41 XHANCE 372 mcg BID vs 0.61 placebo EDS (P<0.001)

Endoscopic video examples of the impact of XHANCE

Patient 1
Reduction from grade 2 to grade 1

Patient 1 - reduction from grade 2 to grade 1

Patient 2
Reduction from grade 2 to grade 0

Patient 2 - reduction from grade 2 to grade 0

Patient 3
Improvement in SNOT-22 score

Patient 3 - Improvement in SNOT-22 score

These results may not be representative of all patients using XHANCE.

A side-by-side example2

  • Patient experienced polyp recurrence following endoscopic sinus surgery
  • Grade 2 nasal polyp located in the left nasal cavity confirmed by rigid endoscopy
  • Patient was not taking any medication for the treatment of nasal polyps but was being treated for asthma
Before Xhance & after using Xhance for 3 months photos
The clinical trials for XHANCE evaluated over 1500 patients.2
See what makes XHANCE different.